Skip to content

The Effect of Sujok Therapy on Cancer Symptoms

The Effect of Sujok Therapy on Pain, Fatigue, Insomnia, Nausea and Vomiting Experienced by Patients With Gastrointestinal System Cancer

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05265754
Enrollment
49
Registered
2022-03-04
Start date
2022-02-01
Completion date
2022-09-05
Last updated
2023-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Keywords

Pain, Insomnia, Fatigue, Nausea and Vomiting, gastrointestinal system cancer., sujok therapy

Brief summary

The aim of this study is to determine the effect of Sujok therapy on Pain, Fatigue, Insomnia, Nausea and Vomiting experienced by patients with gastrointestinal system cancer.

Detailed description

The aim of this study is to determine the effect of Sujok treatment on Pain, Fatigue, Insomnia, Nausea and Vomiting experienced by patients with gastrointestinal system cancer. Intervention and control groups will be determined by randomization. The scales to be used in the measurement will be applied to the individuals included in the study. Then, sujok therapy will be applied to the intervention group. After 6 sessions in weeks in total, measurement tools will be applied and evaluated again.

Interventions

BEHAVIORALsujok therapy

sujok therapy

Sponsors

Ataturk University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Subject)

Intervention model description

6 sessions in 2 weeks in total of sujok therapy will be applied to the interventional group.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* over 18 years old * Fatigue Severity Measurement - Visual Analogue Scale (VAS) fatigue score of 3 and above, * Pain Severity Measurement - Visual Analogue Scale (VAS) pain score of 3 and above, * Measurement of Nausea and Vomiting Severity - Patients with a Visual Analogue Scale (VAS) nausea and vomiting score of 3 and above will be included.

Exclusion criteria

* Loss of sensation, amputation, injury, colostomy, etc., which will prevent practice in hands. patients will be excluded from the study.

Design outcomes

Primary

MeasureTime frameDescription
Sujok Therapy's positive cahange in nausea and vomiting Experienced by Patients with Gastrointestinal System Cancer2 weeksTo evaluate nausea and vomiting, the Rhodes nausea vomiting scale will be applied before starting the sujok application and after the sujok applied for 2 weeks
Sujok Therapy's Positive Change in Pain Experienced by Gastrointestinal System Cancer Patients2 weeksTo assess the pain, the MCgill Pain Scale will be applied before starting the sujok application and after the sujok applied for 2 weeks.
Sujok Therapy's positive change in Fatigue Experienced by Patients with Gastrointestinal System Cancer2 weeksTo assess the fatigue, the cancer fatigue scale will be applied before starting the sujok application and after the sujok applied for 2 weeks.
Sujok Therapy's positive cahange in insomnia Experienced by Patients with Gastrointestinal System Cancer2 weeksIn order to evaluate insomnia,the insomnia severity index will be applied before starting the sujok application and after the sujok applied for 2 weeks

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026